Testing DF-003 for ROSAH syndrome with eye inflammation
Part of Eyes & vision, Genetic & congenital clinical trials.
This trial tests an oral medication called DF-003 for people with ROSAH syndrome who have eye inflammation (uveitis). The goal is to see if the drug is safe and tolerable. It might help reduce eye inflammation and other symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must have been diagnosed with ROSAH syndrome through genetic testing (such as an ALPK1 mutation like T237M, Y254C, or T237A).
- Must have signs of eye inflammation (like swelling of the retina or optic nerve, or leaking blood vessels in the eye).
- Must be between 18 and 65 years old.
- Must have a BMI between 18 and 35.
- Must not be pregnant, breastfeeding, or planning to become pregnant or father a child during the study or for 90 days after.
- Must avoid certain medications (like strong antibiotics, some heart medications, and many herbal supplements) during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies DF-003 in lab tests using blood immune cells taken from people with ROSAH syndrome. It aims to see whether the treatment works in lab “ex vivo” tests and could guide future options.
This study tests an experimental medicine given by IV infusion to see if it is safe and helps reduce symptoms of lupus, sjogren's disease, or rheumatoid arthritis. It is an early-phase trial, so the main goals are checking side effects and how the drug behaves in the body, but it will also look at how well it works.
This trial tests a combination of an anti-inflammatory gel (Hirudoid), yellow light therapy, and two oral medications (tofacitinib and doxycycline) for Chinese adults with mild to moderate rosacea that causes redness and visible blood vessels. The goal is to see if this approach reduces symptoms safely.
This trial tests an injection (PUMCH-E111) for people with a specific genetic form of inherited retinal dystrophy caused by RLBP1 mutations. It aims to see if the treatment is safe and can help preserve vision.
This trial tests a new medicine called UDP-003 in two groups: healthy volunteers and people who had a heart event (acute coronary syndrome) at least a year ago. The goal is to see if the drug is safe and how the body handles it, which could lead to better treatments for heart disease.
This trial tests a new medication called ADI-001 to see if it can help people with rheumatoid arthritis. It is for adults who meet the standard criteria for RA and are in generally good health otherwise.
Hear when a new ROSAH trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.